What is Leerink Partnrs’ Forecast for CGEM Q1 Earnings?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Cullinan Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings of ($0.74) per share for the quarter. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. Leerink Partnrs also issued estimates for Cullinan Therapeutics’ Q2 2025 earnings at ($0.79) EPS, Q3 2025 earnings at ($0.84) EPS and Q4 2025 earnings at ($0.88) EPS.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.09.

CGEM has been the topic of a number of other reports. UBS Group assumed coverage on shares of Cullinan Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $30.00 price objective on the stock. HC Wainwright increased their target price on shares of Cullinan Therapeutics from $28.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cullinan Therapeutics presently has an average rating of “Buy” and a consensus price target of $32.50.

Cullinan Therapeutics Trading Up 0.5 %

Cullinan Therapeutics stock opened at $10.35 on Friday. The firm has a market capitalization of $602.68 million, a P/E ratio of -3.64 and a beta of -0.16. The stock’s fifty day simple moving average is $11.49 and its 200-day simple moving average is $14.96. Cullinan Therapeutics has a twelve month low of $9.50 and a twelve month high of $30.19.

Insider Buying and Selling at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 3,489 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $12.52, for a total transaction of $43,682.28. Following the sale, the insider now owns 104,453 shares in the company, valued at $1,307,751.56. The trade was a 3.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nadim Ahmed sold 8,400 shares of the stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $11.87, for a total transaction of $99,708.00. Following the completion of the sale, the chief executive officer now directly owns 263,150 shares of the company’s stock, valued at $3,123,590.50. This trade represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 20,582 shares of company stock valued at $246,977 in the last ninety days. Company insiders own 6.07% of the company’s stock.

Hedge Funds Weigh In On Cullinan Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new stake in shares of Cullinan Therapeutics in the 2nd quarter valued at $186,000. The Manufacturers Life Insurance Company lifted its stake in shares of Cullinan Therapeutics by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,175 shares of the company’s stock valued at $265,000 after purchasing an additional 4,393 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Cullinan Therapeutics by 18.3% during the third quarter. Assenagon Asset Management S.A. now owns 135,036 shares of the company’s stock worth $2,261,000 after buying an additional 20,841 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Cullinan Therapeutics by 64.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,151 shares of the company’s stock valued at $187,000 after purchasing an additional 4,380 shares during the period. Finally, Harbor Capital Advisors Inc. raised its stake in Cullinan Therapeutics by 22.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 21,362 shares of the company’s stock worth $358,000 after buying an additional 3,881 shares during the period. Institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.